Insight to shape decisions.
Experience to deliver.
Senior-level business development and corporate strategy advisory for biopharma leaders, boards and investors navigating high-stakes opportunities.
Discover our approachIndependent thinking.
Seasoned judgment.
Hands-on execution.
SSZ Life Science Consulting partners directly with CEOs, boards and investors to translate complex scientific, commercial and financial considerations into decisive strategic action.
Founded by Sanjay Zaveri, RPh, MBA, the firm draws on more than 25 years spanning biopharma executive leadership, business development and top-tier life sciences consulting. We combine strategic perspective with the practical experience needed to structure and execute transactions.
Our engagement model is deliberately personal: senior-led advice, direct access and focused accountability from strategy through execution.
experience
across career
across sectors
to Xeris
Strategic counsel at
critical inflection points.
Focused support for emerging and established biopharma companies—from portfolio choices and capital strategy to partnerships and transformative transactions.
Corporate &
Portfolio Strategy
Corporate development planning, strategic alternatives, asset prioritization, enterprise valuation and board-level decision support.
Business Development
& Licensing
Partner identification, asset screening, due diligence, deal structuring, negotiation, in- and out-licensing and M&A execution.
Commercial &
Investment Strategy
Market assessment, forecasting, competitive positioning, commercialization pathways and investor-facing strategic narratives.
Experience where the
stakes are high.
Recent assignments include strategic advisory engagements in obesity, cardiovascular therapeutics and RNAi. Active client relationships are described by sector to respect confidentiality.
Advised leadership on commercial and business development strategy for its obesity portfolio, contributing to strategic positioning ahead of its acquisition by Pfizer. This describes an advisory role, not leadership of the acquisition transaction.
Business development leadership supporting in- and out-licensing opportunities, strategic partnerships and corporate development priorities.
Commercial forecasting and channel strategy supporting a preventive cardiovascular medicine development program.
More than a decade in the life sciences consulting practice, advising pharmaceutical and biotechnology companies on corporate strategy, commercial evaluation, licensing, M&A, forecasting, valuation and transaction diligence. Supported strategic analysis for the $805 million Daiichi Sankyo / Plexxikon acquisition.
Head of Business Development & Corporate Strategy. Led strategic processes culminating in the $267 million sale to Xeris, and executed a $145 million-plus out-license and equity arrangement with Novo Nordisk.
SVP, Head of Business Development & Corporate Strategy. Negotiated a global licensing agreement with Merck KGaA, including milestone potential and royalties.
Served as contract Chief Business Officer, leading enterprise development, partnership strategy, new-venture pathways and engagement with biotechnology investors.
Sanjay Zaveri
RPh, MBA
Across executive positions at Strongbridge Biopharma, PDS Biotech and RefinedScience—and more than a decade with Navigant / Guidehouse—Sanjay has worked at the intersection of science, strategy and transaction execution.
He brings expertise across obesity and metabolic disease, cardiovascular therapeutics, oncology, rare disease and specialty pharma.
View professional profileExperienced perspective.
Focused on what comes next.
Discuss your strategic priorities, partnership opportunities or need for senior-level corporate development leadership.
Contact SSZ ↗